- Merck KGaA to acquire Silence Therapeutics for $1.1 billion, gaining Phase 3 PV siRNA assetMerck KGaA announced it will buy Silence Therapeutics for about $1.1 billion, giving the German group a foothold in hematology. Silence, a UK-based RNA specialist, develops short interfering RNA m…
- Merck/Moderna vaccine and Summit/Akeso bispecific therapy among key highlights at ESMO 2026The European Society of Medical Oncology (ESMO) meeting in Madrid this weekend will showcase several high‑profile oncology programs. Among the most watched are Merck and Moderna’s personalized can…